Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates

Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of a loss of$ 0.08 per share. This compares to loss of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 525%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.53 per share when it actually produced a loss of $0.50, delivering a surprise of 5.66%.Over the last four ...